Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (468)	1/23/1998 10:35:00 PM
From: 5,17,37,5,101,...	Respond to of 756

I can find no sales figures for SmithKline Beecham's compazine. Any clues? I've hit their web page and financials and psychiatric lit. This makes 4 drug approvals in the last month, about. At that rate, Ivax will have 48 approvals this year. Even if we count on 10 approvals and maybe 2 or 3 blockbusters, you're looking at a share price of 13. Jackson

To: flickerful who wrote (468)	1/23/1998 10:51:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

I sort of answered my own question. This approval doesn't even merit the last page of Hustler Magazine. See: duramed.com Duramed's generic version was approved 5/97! And apparently the drug is somewhat controversial, fraught with side effects, and the target of those who would see cannabis supplant it as the anti-nausea drug of choice. dentalbiz.com rxcannabis.org However, I must presume insiders weren't buying on THIS news. We might infer that there is bigger and better news on the horizon. Shorts...where are you? Jackson